Phase 3 Readout~month

Phase 3 Topline: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of

Name: Phase 3 Topline: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of
Start: 2028-04-01

April 1, 2028

Company: LeonaBio, Inc. (LONA)
Drug: locally
Indication: Metastatic Breast Cancer

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of — LONA Phase 3 Readout | BioSniper